ConductScience.org, home

Paper11041565

Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia.

Baker KS and 5 others. Bone Marrow Transplant, 2000. Cited by 23 papers, by iCite.

Cite this record

ConductScience Library. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia. Papers, record 11041565. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11041565

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia.
PubMed
Journal
Bone Marrow Transplant
PubMed
Year
2000
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
23
iCite
Relative citation ratio, by iCite
0.72
iCite
Revised in PubMed
2026-10-10
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Baker KSK S
2Bostrom BB
3DeFor TT
4Ramsay NKN K
5Woods WGW G
6Blazar BRB R

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, AlkylatingMajor topic
BusulfanMajor topic
Hematopoietic Stem Cell TransplantationMajor topic
Immunosuppressive AgentsMajor topic
Leukemia, MyeloidMajor topic
Acute Disease
Adolescent
Adult
Child
Child, Preschool
Combined Modality Therapy
Disease-Free Survival
Female
Graft vs Host Disease
Humans
Infant
Male
Middle Aged
Remission Induction
Survival Rate
Transplantation Conditioning

Source PubMed

Download CSV of topics

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18269597Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/8269597PubMed
22591002Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation.Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2591002PubMed
37803883Busulfan.Ann Pharmacother1994https://conductscience.org/library/papers/7803883PubMed
47919328Busulfan bioavailability.Blood1994https://conductscience.org/library/papers/7919328PubMed
58882952Aspects concerning busulfan pharmacokinetics and bioavailability.Leuk Lymphoma1996https://conductscience.org/library/papers/8882952PubMed
67581127Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics.Bone Marrow Transplant1995https://conductscience.org/library/papers/7581127PubMed
79196136
Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.
J Clin Oncol1997https://conductscience.org/library/papers/9196136PubMed
818820Bone marrow transplantation in the busulfin-treated rat. III. Relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients.Transplantation1977https://conductscience.org/library/papers/18820PubMed
91571560Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?Blood1992https://conductscience.org/library/papers/1571560PubMed
106372650Graft-versus-host disease: pathophysiological and clinical aspects.Annu Rev Med1984https://conductscience.org/library/papers/6372650PubMed
112861312Marrow transplantation for thalassaemia following busulphan and cyclophosphamide.Lancet1985https://conductscience.org/library/papers/2861312PubMed
128932835Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.Bone Marrow Transplant1996https://conductscience.org/library/papers/8932835PubMed
132060084Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology.Cancer Chemother Pharmacol1991https://conductscience.org/library/papers/2060084PubMed
148712747Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo).Anticancer Res1996https://conductscience.org/library/papers/8712747PubMed
151421415Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation.Blood1992https://conductscience.org/library/papers/1421415PubMed
169028555Growth after bone marrow transplantation in young children conditioned with chemotherapy alone.Bone Marrow Transplant1997https://conductscience.org/library/papers/9028555PubMed
178338934Busulfan disposition below the age of three: alteration in children with lysosomal storage disease.Blood1993https://conductscience.org/library/papers/8338934PubMed
182791192Pharmacokinetics of high-dose busulfan in children.Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2791192PubMed
198888742Growth in children undergoing bone marrow transplantation after busulfan and cyclophosphamide conditioning.J Pediatr Hematol Oncol1996https://conductscience.org/library/papers/8888742PubMed
202328321Busulfan disposition in children.Blood1990https://conductscience.org/library/papers/2328321PubMed

See all 35 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.

PMIDTitleJournalYearIn PapersSource
35784763The Correlation Between Busulfan Exposure and Clinical Outcomes in Chinese Pediatric Patients: A Population Pharmacokinetic Study.Front Pharmacol2022https://conductscience.org/library/papers/35784763PubMed
34956984Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia.Front Pediatr2021https://conductscience.org/library/papers/34956984PubMed
31578451Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial.Leukemia2020https://conductscience.org/library/papers/31578451PubMed
29608607Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children.PLoS One2018https://conductscience.org/library/papers/29608607PubMed
29207608GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study.Oncotarget2017https://conductscience.org/library/papers/29207608PubMed
25347008Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics.Bone Marrow Transplant2015https://conductscience.org/library/papers/25347008PubMed
23444282Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.J Clin Pharmacol2013https://conductscience.org/library/papers/23444282PubMed
15480668Autologous stem cell transplantation in hematological malignancies.Springer Semin Immunopathol2004https://conductscience.org/library/papers/15480668PubMed
15195074Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages.Bone Marrow Transplant2004https://conductscience.org/library/papers/15195074PubMed
13130310Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.Bone Marrow Transplant2003https://conductscience.org/library/papers/13130310PubMed
12953124Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study.Bone Marrow Transplant2003https://conductscience.org/library/papers/12953124PubMed
12189535Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.Bone Marrow Transplant2002https://conductscience.org/library/papers/12189535PubMed
11781625Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.Bone Marrow Transplant2001https://conductscience.org/library/papers/11781625PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/11041565

GET https://conductscience.org/api/papers/v1/11041565/references?page=2